Family planning options, including hormonal contraceptives, are essential for improving reproductive health among HIV-infected women. For these individuals, prevention of unintended pregnancy decreases maternal and child mortality, as well as reduces the risk of mother-to-child HIV transmission. Similarly, antiretroviral therapy (ART) is essential for reducing morbidity and mortality among HIV-infected individuals, in addition to preventing HIV transmission. Thus, it is of critical public health importance to safely combine hormone contraceptives and ART. Millions of HIV-infected women on ART currently use subdermal progestin-releasing implants as a preferred method of long-acting, reversible contraception despite the lack of critically needed pharmacokinetic (PK) drug-interaction data to inform their safe and effective concomitant use. Highlighting this concern, our research team recently demonstrated that combined use of efavirenz (EFV)-based ART, the only preferred first-line ART regimen in low- and middle-income countries, with a levonorgestrel (LNG)-releasing implant for one year reduced LNG plasma concentrations by approximately 50% compared to women not on ART. Importantly, we also observed three unintended pregnancies (15%) in our study group of women on EFV-based ART plus the LNG implant, in contrast to the <1% expected failure rate of the implant for women without drug interactions. Still, subdermal implants remain an essential family planning option and are routinely co-prescribed with ART. Therefore, the overall goal of this proposed study is to build upon and extend our prior work in order to provide comprehensive, evidence-based guidance on the use of LNG implants with ART in HIV-infected women. Overall, we hypothesize that detrimental drug-drug interactions between the LNG implant and EFV-based ART can be overcome by using an increased dose of the LNG implant and/or alternative ART combinations. We will accomplish this through the following three specific aims:
Aim 1) determine if increasing the dose of the LNG-releasing subdermal implant effectively overcomes the known PK interaction with EFV- based ART;
Aim 2) predict optimal strategies to comprehensively combine LNG implants with ART options using physiologically-based PK (PBPK) modeling;
and Aim 3) determine the in vivo PK of LNG released from a subdermal implant over one year in combination with emerging ART strategies. Collectively, these aims significantly extend our preliminary findings to identify a strategy to overcome the drug-drug interaction between LNG and EFV-based ART, advance contraceptive therapeutic options for HIV-infected women, and advance the science of the drug-drug interaction field. Overall, our proposed study will provide an evidence- based approach to safely combine LNG implants with ART regimens spanning the continuum of HIV care. In turn, this collaborative study is strongly expected to improve the management of reproductive health in millions of HIV-infected women worldwide.
The use of hormonal contraceptives presents a significant challenge for the estimated 16 million HIV-infected women of childbearing age due primarily to drug interactions that can be caused by medications used to treat HIV. Based on our preliminary data, certain drug interactions appear to increase the chance of pregnancy while using hormonal contraceptives. To address this, our proposed study will evaluate practical strategies for the use of a levonorgestrel contraceptive implant, which is the most widely available hormone implant in low and middle-income countries, in HIV-infected women. Thus, our results will guide co-management of these important medications, and are thereby expected to reduce unintended pregnancies, improve maternal and child mortality, and decrease the rate of mother-to-child HIV transmission.
|Cirrincione, Lauren R; Penchala, Sujan Dilly; Scarsi, Kimberly K et al. (2018) Development, validation and utilization of a highly sensitive LC-MS/MS method for quantification of levonorgestrel released from a subdermal implant in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 1084:106-112|
|Podany, Anthony T; Bares, Sara H; Havens, Joshua et al. (2018) Plasma and intracellular pharmacokinetics of tenofovir in patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide. AIDS 32:761-765|
|Roberts, Owain; Rajoli, Rajith K R; Back, David J et al. (2018) Physiologically based pharmacokinetic modelling prediction of the effects of dose adjustment in drug-drug interactions between levonorgestrel contraceptive implants and efavirenz-based ART. J Antimicrob Chemother 73:1004-1012|
|Neary, M; Lamorde, M; Olagunju, A et al. (2017) The Effect of Gene Variants on Levonorgestrel Pharmacokinetics When Combined With Antiretroviral Therapy Containing Efavirenz or Nevirapine. Clin Pharmacol Ther 102:529-536|
|Chappell, Catherine A; Lamorde, Mohammed; Nakalema, Shadia et al. (2017) Efavirenz decreases etonogestrel exposure: a pharmacokinetic evaluation of implantable contraception with antiretroviral therapy. AIDS 31:1965-1972|
|Patel, Rena C; Morroni, Chelsea; Scarsi, Kimberly K et al. (2017) Concomitant contraceptive implant and efavirenz use in women living with HIV: perspectives on current evidence and policy implications for family planning and HIV treatment guidelines. J Int AIDS Soc 20:21396|
|Podany, Anthony T; Scarsi, Kimberly K; Fletcher, Courtney V (2017) Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors. Clin Pharmacokinet 56:25-40|
|Scarsi, Kimberly K; Darin, Kristin M; Chappell, Catherine A et al. (2016) Drug-Drug Interactions, Effectiveness, and Safety of Hormonal Contraceptives in Women Living with HIV. Drug Saf 39:1053-1072|